Description
Composition- Linagliptin 2.5 mg + Metformin 500 mg
Mode of Action- Combines DPP-4 inhibition with metformin-mediated reduction in hepatic glucose output and improved insulin sensitivity.
USPs- Balanced dual therapy; useful in early and moderate type 2 diabetes; supports comprehensive glycemic control.
Prescribing Specialties- Diabetologist, General Physician
